FTC SUIT AGAINST DAHLBERG SEEKS CIVIL PENALTIES
This article was originally published in The Gray Sheet
Executive Summary
At a Jan. 25 news conference announcing the FTC suit, Christian White, Acting Director of the FTC Bureau of Consumer Protection, said the case against Dahlberg "is about combating false advertising that may lead to unrealistic consumer expectations." Stressing the "difficult decision" consumers often face when buying a hearing aid, White said the commission's goal is to ensure that misleading information does not result in a "futile purchase."
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.